首页 | 本学科首页   官方微博 | 高级检索  
     


Management of fingolimod in clinical practice
Authors:Katja Thomas  Tjalf Ziemssen
Affiliation:1. Division of Vascular Endothelium and Microcirculation, Department of Medicine III, University Clinical Center, University Hospital Carl Gustav Carus, Dresden University of Technology, Fetscherstr. 74, 01307 Dresden, Germany;2. Autonomic and Neuroendocrinological Laboratory, Center of Clinical Neuroscience, Department of Neurology, University Clinical Center, University Hospital Carl Gustav Carus, Dresden University of Technology, Fetscherstr. 74, 01307 Dresden, Germany;3. Department of Medicine III, University Clinical Center, University Hospital Carl Gustav Carus, Dresden University of Technology, Fetscherstr. 74, 01307 Dresden, Germany;4. Lipoprotein Apheresis Center, Department of Medicine III, University Clinical Center, University Hospital Carl Gustav Carus, Dresden University of Technology, Fetscherstr. 74, 01307 Dresden, Germany;1. MS Center Dresden, Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany;2. Centre for Ophthalmology, Eberhard-Karl-University Tuebingen, Tuebingen, Germany;1. Clinic of Neurology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 6, 11129 Belgrade, Serbia;2. Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Visegradska 26A, 11129 Belgrade, Serbia
Abstract:The efficacy of the innovative oral drug fingolimod has been proven in the largest study program in multiple sclerosis (MS) demonstrating reduced relapse and reduced disability progression in relapsing-remitting MS patients. Based on the extensive safety data of all clinical trials and the natural distribution pattern of fingolimod interacting receptors in organism, careful clinical monitoring is recommend and reviewed in this paper. Safety and tolerability data from clinical studies as well as current post-marketing experience present with high tolerability and easy-to-perform management of fingolimod. Here we present the recommended management of fingolimod in clinical practice starting with preparatory steps, first-dose application and long-term treatment period with fingolimod. This management of fingolimod in clinical practice ensure a safe treatment algorithm using fingolimod. We recommend documentation of fingolimod patients in clinical registries to generate postmarketing data on efficacy and safety of fingoilimod.
Keywords:Multiple sclerosis  Clinical practice  Clinical management  Safety  Registry
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号